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Abstract We designed a mathematical model to describe
and quantify the mechanisms and dynamics of tumor
growth, cell-kill and resistance as they affect durations of
benefit after cancer treatment. Our aim was to explore how
treatment efficacy may be related to primary tumor char-
acteristics, with the potential to guide future trial design
and appropriate selection of therapy. Assuming a log-nor-
mal distribution of both resistant disease and tumor dou-
bling times generates disease-free survival (DFS) or
invasive DFS curves with specific shapes. Using a multi-
variate mathematical model, both treatment and tumor
characteristics are related to quantified resistant disease and
tumor regrowth rates by allowing different mean values for
the influence of different treatments or clinical subtypes on
these two log-normal distributions. Application of the
model to the CALGB 9741 adjuvant breast cancer trial
showed that dose-dense therapy was estimated to achieve
an extra 3/4 log of cell-kill compared to standard therapy,
but only in patients with more rapidly growing ER-nega-
tive tumors. Application of the model to the AZURE trial
of adjuvant bisphosphonate treatment suggested that the
5-year duration of zoledronic acid was adequate for ER-
negative tumors, but may not be so for ER-positive cases,
with increased recurrences after ceasing the intervention.
Mathematical models can identify different effects of
treatment by subgroup and may aid in treatment design,
trial analysis, and appropriate selection of therapy. They
may provide a more appropriate and insightful tool than the
conventional Cox model for the statistical analysis of
response durations.
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Introduction
Mathematical models that incorporate information regard-
ing tumor biology have the potential to provide mecha-
nistic insights derived from trial data that cannot be gained
by conventional statistical methods. We describe an
approach that directly estimates the underlying biological
parameters which generate particular DFS/IDFS curves.
Previous work
A previously published mathematical model [1, 2] related
outcome durations to the amount of sub-clinical resistant
disease and to tumor regrowth rates. Briefly, the model
relates certain patterns in the shapes of DFS curves [1] to
underlying quantity of undetectable resistant disease post-
treatment, and the rate of tumor regrowth. Plateaus on the
curves, gradients of the slopes, and the relationship
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between the height of the plateau and the delay on the
curve before relapses start to occur, are all incorporated
and explained by the model. It was hypothesized that DFS
curves for faster growing tumors would have steeper
slopes, and that the frequency and intensity of treatment
should be matched to the aggressive growth of the tumor.
In the management of a number of early-stage solid
cancers, primary surgical treatment removes the bulk pri-
mary tumor; the volume of any remaining disease being
below the level of clinical detection. Based on tumor char-
acteristics and pathological stage, adjuvant therapies may
then be applied with the goal of reducing or eradicating this
clinically undetectable residual disease. Clinical relapse
occurs when tumor regrowth exceeds this level of detection.
The model assumes that the component of this disease that is
resistant to the adjuvant treatment employed is that which is
destined to regrow and cause subsequent relapse, and that the
volume of this resistant disease is log-normally distributed
over the population of patients under consideration [1].
Adjuvant treatment is assumed to eradicate sensitive disease,
but to be ineffective against resistant disease. In the event of
the resistant disease being less than a given log volume (not
necessarily 1 cell), the patient is assumed to be cured.
Otherwise, the resistant disease is assumed to grow expo-
nentially during and after treatment until relapse occurs, with
the rate of regrowth being taken from a log-normal distri-
bution of doubling times (Fig. 1). Similar model assump-
tions have been applied to other cancers [1, 5, 6].
The model assumptions give rise to DFS curves with the
desired shapes, enabling differences in curves to be ascri-
bed to effects on either resistant disease burden at the end
of treatment or subsequent regrowth rates. The ‘‘plateau’’
in the curve results from allowing for the possible extinc-
tion of the tumor when reduced below a given level.
Rapidly growing tumors have a steeper curve slope. Curves
with a pronounced delay before relapses start to occur are
likely to have lower volumes of resistant disease, and
therefore a higher plateau.
New model developments
The model has now been solved explicitly (see supple-
mentary methods) and extended to a multivariate form.
With the new model, prognostic factors can be related to
components of both the regrowth rate and the level of
undetectable resistant disease, potentially providing
hypotheses for future tailoring of treatment. Measurable
factors likely to be related to the volume of post-treatment
resistant disease would include, as an example, primary
tumor size at presentation [2], while those expected to
correlate with tumor growth rates would include the his-
tological grade of tumor, and markers of proliferation such
as Ki67 [3, 4].
To demonstrate how the shape of the DFS curves relates
to the underlying parameters, Fig. 2a, b show hypothetical
curves from the original application [1] to treatments for
acute myeloid leukemia (AML) [7] that produce purely
resistant disease burden (effectively cell-kill) effects
(Fig. 2a), compared with those that produce purely growth
rate-related effects (Fig. 2b). In the latter case the curves
diverge initially, but then gradually come back together,
while in the former case divergence continues until relap-
ses cease. The maximum likelihood algorithm effectively
locates the closest such fits with a particular set of model
assumptions (see supplementary methods).
This new multivariate mathematical model does not
require proportional hazards, and therefore may also be
more appropriate than the Cox model [8], for the analysis
of these types of data.
Applications
Model applications to the CALGB 9741 and AZURE
adjuvant breast cancer trials [9–11] are presented. The
CALGB study employed a dose-dense chemotherapy
schedule, based on the work of Norton and Simon [12, 13].
The dose-dense treatment, with shorter treatment intervals
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Fig. 1 Diagrammatic representation of the model: a assumed distri-
bution of resistant disease after adjuvant treatment, b assumed pattern
of regrowth rates of resistant disease
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would theoretically kill rapidly dividing cells more effec-
tively, making it a good study in which to test the ability of
the model to show differential effects on groups of patients
with different tumor growth rates. In contrast, zoledronic
acid, the bisphosphonate evaluated in the AZURE trial,
differed in that its potential mechanism(s) of action was not
understood and that bisphosphonate efficacy in the adju-
vant setting was unproven. There was no a priori expec-
tation that there would be any specific subgroup that would
demonstrate a treatment effect. Information on several
growth-related prognostic factors was, however, available
affording the potential to evaluate treatment/growth rate
interactions.
Methods
The model
The model, outlined in the introduction, is described
mathematically in the supplementary methods section, with
diagrammatic representation in Fig. 1. The new multi-
variate version assumes that the means of the two log-
normal distributions can be related to both treatment and
tumor characteristics in a linear multiplicative fashion,
thereby producing different DFS curves for different
treatment/prognostic groups.
Application of the model
The model is applied to DFS times, complete and censored,
and a set of treatment/prognostic factors are then examined
for their relationship to these durations of response, via
effects on resistant disease and growth rates, using a for-
ward stepwise approach (see supplementary methods).
Factors can be included for their effects both on growth
rates and/or resistant disease. The significance of a
covariate, if required, can be evaluated by testing the pair
of parameters together, namely resistant disease and dou-
bling time, in the new model. Related computer programs
are available (see supplementary methods).
Model assumptions
The model assumes exponential growth. Alternative
growth rate assumptions, such as the gompertzian model
proposed by Norton [14], were considered; the model is,
however, attempting to estimate the growth rate of sub-
clinical disease, where the gompertzian model is less rel-
evant. The assumption of a log-normal distribution of
growth rates is consistent with other findings [15, 16].
The volume of resistant disease after treatment is
assumed to be independent of its growth rate, consistent
with results from an independent set of data from CLL
(data not shown). The original rationale for assuming a log-
normal distribution of resistant disease [1, 5, 6] was related
to a Goldie/Coldman mathematical model where random
spontaneous mutations conferred drug resistance over a
tumor’s lifetime [2]; this assumption was shown to lead to
a log-normal distribution of resistant tumor at presentation
[5]. The situation is somewhat different with operable
breast cancer treated initially by surgery, with or without
radiotherapy, where the local disease has been effectively
eliminated but the cancer may have disseminated through
vascular or lymphatic channels [16]. Before diagnosis, as
the tumor increases in size, the likelihood of occult distant
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Fig. 2 Hypothesized effect on the duration of 1st complete remission
(CR) for patients in the MRC AML 8 trial of a 1-log improvements in
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Breast Cancer Res Treat
123
metastases developing increases. Thus, we can assume a
random spontaneous chance of mutations to a metastatic
phenotype developing and cells becoming disseminated,
which increases over time, with a similar pattern of
mutation to resistance; this results in a log-normal distri-
bution of, in this case, disseminated resistant disease at
presentation.
Note that it is assumed that C109 cells are clinically
detectable, and that all these cells need to be eliminated to
eradicate the disease. The choice of this level, which is the
same for all covariates, does not affect the shape of the
distribution of growth rates or the fitting process; it merely
affects the doubling time estimates. The model estimates
for doubling times under this assumption are consistent
with those reported in breast cancer [15].
Model-based DFS curves and comparison
with the Cox model
Model fits for both models can be shown by deriving an
estimated survival curve for each prognostic category,
taking into account the mix of treatment and prognostic
factors that determine a specific resistant disease volume
and growth rate, averaging these survival figures over a
group of patients, for example those with ER-positive
disease, then validating this by comparison with the actu-
arial curve (see Figs. 3, 4, and 5 and supplementary Fig. 1).
Akaike’s Information Criterion (AIC) [17] allows for the
(four) extra parameters in this new model in comparison
with the partial likelihood derived from the Cox model and
facilitates an order-of-magnitude comparison of the fits of
the two models (see supplementary methods).
Application data/studies
CALGB study 9741 treated 1973 women with node-posi-
tive breast cancer. One of the two randomizations in this
study tested dose-dense chemotherapy comprising dox-
orubicin, cyclophosphamide, and paclitaxel given every
two weeks versus a conventional schedule given every
three weeks [9, 10]. Berry et al. [10] broke down the results
by ER status demonstrating a 24 % [95 % CI 1–42 %]
reduction in risk of recurrence for women with ER-nega-
tive tumors, but a non-significant risk reduction of 8 %
[95 % CI 20–29 %] in ER-positive cases at a median fol-
low-up of 6 years.
The AZURE trial [11] tested the hypothesis that bis-
phosphonate treatment may reduce rates of recurrence and
death in 3360 women with high risk early breast cancer,
with axillary lymph node metastasis (N1) or T3/T4 primary
tumors. Consenting patients were randomized to receive
standard adjuvant systemic therapy with or without zole-
dronic acid following local treatment. Zoledronic acid
treatment was planned for 5 years duration. The median
follow-up at the time of reporting was 7 years. Zoledronic
acid was effective only in postmenopausal women
(n = 1041), with an IDFS hazard ratio of.75 [95 % CI 59–
.96]. Efficacy in this subgroup was later verified in a meta-
analysis of other studies [18]. This analysis focuses on
invasive disease-free survival (IDFS).
Reconstructing DFS data
Published DFS graphs from CALGB 9741 [10] were
scrutinized and individual survival times were successfully
derived, ensuring that all p-values, confidence intervals
(CIs), numbers of events, median DFS times, and durations
of patient follow-up matched those reported. For the
AZURE trial individual patient data were provided by the
Leeds Clinical Trials Research Unit.
Results
CALGB 9741
The associated DFS curves for study 9741, along with the
model fits, are given in Fig. 3a. From the model results
dose-dense therapy was estimated to produce 3/4 log of
additional cell-kill in women with ER-negative disease,
which equates to an additional 10 % of these women being
cured. The associated distribution of resistant disease is
shown in Fig. 3b, and comparison with the Cox model DFS
estimates are shown in Fig. 3c. The model clearly attrib-
uted the difference in ER status DFS curves to a large
difference in mean doubling times: 31 days for ER-nega-
tive women compared with 84 days for ER-positive
women (Fig. 3d).
Azure
Model analyses again attributed ER status differences in
IDFS to a difference in growth rates, with estimated mean
doubling times of 39 and 114 days for ER-negative and
ER-positive women, respectively (shown graphically in
supplementary Fig. 1). In support of this finding ER status
was also highly correlated with tumor grade (see Table 1).
Model fits to the two treatment arms in postmenopausal
women are shown in Fig. 4a. The curves appear to show a
possible fall-off after 5 years, which coincides with stop-
ping treatment, and so the model was re-run using data up
to 5 years only, with data after this time being censored.
The model fits are shown in Fig. 4b. Since this is a
mathematical model, it is possible to extrapolate these
curves beyond the 5 years of data that were used to fit the
curves, as in Fig. 4c to predict IDFS with continuation of
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treatment. For the zoledronic acid group there was a
marked divergence from the predictions starting immedi-
ately at the cessation of treatment at 5 years (Fig. 4d).
However, the divergence occurs only in women with ER-
positive disease (Fig. 5a), not those with ER-negative
disease (Fig. 5b). For the control arm the predictions were
much more accurate, only beginning to diverge, if at all, at
about 7 years, when the numbers at risk are small and the
confidence intervals in the IDFS curves are wide. To test
whether these differences from model predictions after
5 years are chance findings IDFS times were generated to
match the modeled pattern beyond 5 years and compared
with the actual data beyond 5 years using a landmark
analysis beginning at 5 years. This revealed a highly sig-
nificant difference between actual data and predicted data
in the zoledronic acid group (p = .0014, Wilcoxon test)
compared with a non-significant difference in the control
group (p = .22, Wilcoxon test) confirming that this is not
simply a chance effect.
Stepwise biological model results for tumor grade, size,
nodal status, and ER status are given in detail in supple-
mentary Table 1. Hazards were clearly not proportional for
ER status or for histological grade (p\ .001) resulting in
poor fits for the Cox model, whereas, in contrast, the new
model incorporates such effects explicitly and exhibits
good fits (see supplementary Fig. 1). AIC differences
confirm these interpretations, and are presented in the
supplementary methods. The fits for the two models for
T-stage and for the number of involved lymph nodes were
similar.
Discussion
This new biologically based model demonstrates that it is
possible to determine, in a logical and structured fashion,
interrelationships between treatment and biological factors
of the primary tumor, via their effects on the crucial
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Table 1 Correlation between histological grade and ER status in the
AZURE trial
ER ?ve ER -ve % ER ?ve v2 (trend)
Grade 1 86 0 100 157.2
(p\ .0001)Grade 2 410 44 90
Grade 3 265 202 57
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parameters of resistant sub-clinical tumor burden and
growth rates.
The model we developed resulted in additional results
and hypotheses over and above those obtained from con-
ventional trial analyses. Women with ER-negative breast
cancer are estimated to have more rapid tumor growth
rates; they may, therefore, receive benefit from more fre-
quent chemotherapy, as was demonstrated with accelerated
chemotherapy in the CALGB 9741 study [10]. Further
evidence to support this comes from an analysis of the
CALGB 8541 trial, which tested lower doses/shorter
durations of adjuvant CAF chemotherapy [10]. In that
study, for women with ER-negative disease, who would be
expected to have more rapidly proliferating tumors, 4
cycles of standard CAF chemotherapy was superior to 6
cycles of lower dose CAF; by contrast, for those with more
slowly proliferating ER-positive disease lower dose CAF
given for a longer duration was equally effective [10].
Differential effects of treatment by ER status are
particularly pronounced in both breast cancer datasets,
though similar personalizing of therapy could be consid-
ered within different histological grade, or genomic sub-
groups. This model will outperform standard models such
as the Cox model where factors relate to growth rate dif-
ferences, which are unlikely to fit the proportional hazards
assumption.
What distinguishes this new model from the classical
statistical approach of the Cox model is the incorporation
of an a priori understanding of biological mechanisms; it
does not require the often flawed assumption of propor-
tional hazards, yet produces substantially better model fits
in these breast cancer DFS/IDFS datasets than does the
equivalent Cox model (see Fig. 3 and supplementary
Fig. 1). Interactions with time, and stratification by non-
proportional hazards variables such as ER status, can, of
course, be incorporated into Cox models to avoid the
assumption that hazard ratios are constant across time, but
at the cost of added complexity often making the results
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difficult to understand. This model, in contrast, produces
results that relate to the very biological parameters that the
researchers are usually trying to affect in the trial design,
and are therefore meaningful and directly interpretable.
The distinction between these two approaches is significant
since our model offers the prospect of developing a clini-
cally useful framework for cancer treatment that incorpo-
rates the increasingly sophisticated understanding of tumor
biology gained from experimental studies. Such a frame-
work could include features such as measures of tumor
genome heterogeneity [19] and consequent evolutionary
dynamics [20]. The former might be reflected, for example,
in the parameters describing resistant volume and growth
rate. Such models could incorporate factors such as phar-
macokinetic parameters and have the potential to inform
personalized treatment regimens [21, 22]. Because this
approach is mathematical, it offers a rigorous and
quantitative approach to integrating various aspects of
tumor biology and determining the consequences for
therapy [23].
Applying the insights gained from the CALGB study,
we can consider the AZURE results in the light of factors
relating to tumor growth rate. Firstly, the correlation
between ER status and tumor grade again supports the
conclusion derived from the model analyses that ER-neg-
ative women have faster growing tumors. Then considering
the treatment effect by ER status, a fall-off in the IDFS
curves at 5 years is only seen in the women with ER-
positive disease not in those with ER-negative disease
(Fig. 5a, b). We have not found departures such as this to
be common, and we have now had considerable experience
of using this model across a range of cancers. This analysis
therefore suggests that 5 years of zoledronic acid treatment
is adequate in women with the faster growing ER-negative
tumors, but perhaps insufficient for those with more slowly
proliferating ER-positive tumors who continue to relapse at
a significant rate well beyond the 5 year time point. This
conclusion would not have been forthcoming from the Cox
model, which does not deal well with growth rate effects.
Although zoledronic acid has a long half-life in bone, there
may be a threshold of residual activity and inhibition of
bone turnover required for benefit to occur. Tumor dor-
mancy is also a much more prominent feature in ER-pos-
itive disease and may well be of relevance to these
findings, with[50 % of relapses beyond 5 years reflecting
the late, unexplained, emergence of disseminated tumor
cells from the dormant state [24]. Continuous long-term
application of treatment appears necessary to prevent this
re-awakening of quiescent ER-positive cells unlike the
highly proliferative ER-negative disseminated cells which
are typically either eradicated by adjuvant treatments or
initiate clinically detectable metastases over a much shorter
timeframe (typically\5 years). It is intriguing that recent
data suggest longer duration of treatment may also benefit
patients receiving adjuvant tamoxifen therapy [25–27]. We
do not, therefore, assume this effect to be specific to bis-
phosphonates. The findings are consistent with the long
duration of therapy that is now the standard of care in
hormone-receptor positive breast cancer, with 5 years as a
minimum standard, and with several studies supporting
extended therapy to 10 years [28, 29]. Thus, the model may
lead to the generation of novel treatment strategies, as did
the original univariate model [1] in acute lymphoblastic
leukemia, Hodgkin’s disease, multiple myeloma, and
breast cancer [6].
It is well recognized that cancers are not homogenous
with regard to biology and natural history. This was first
documented in breast cancer with the recognition that
women with ER-positive disease were more at risk of late
relapse than those with ER-negative disease. As molecular
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and genetic understanding grows in this and other cancers,
identification of patients with different outcomes will be
increasingly possible. The model demonstrates that it is
possible to determine these differences, and their potential
interactions with treatment, by modeling the ‘‘shape’’ of the
DFS/IDFS curves. Furthermore, with that insight, the
mathematical model allows predictions to be made of the
long-term benefit beyond the period of follow-up of the
study and generate hypotheses that can be tested in
prospective randomized trials. This model, as with all such
models, represents a considerable simplification of tumor
dynamics, since it does not, at present, explicitly incorpo-
rate current understanding of immune signaling, angio-
genesis, stem-cell subpopulations, and other important
host-tumor interactions, but unless they are thought to act
other than on the net tumor doubling time and resistant
disease volume, their effects could still be estimated. As
more data are generated on the biological and genetic
characteristics of cancers, this approach may be further
developed and additional complexity included as required.
Concepts derived from mathematical modeling have
been productive in generating new trials and treatment
approaches, for instance of alternating non-cross resistant
drug combinations as proposed by Goldie et al. [30], or
hypotheses regarding proportional cell-kill and its
exploitation as suggested by Skipper et al. [31, 32]. More
recently, and since the publication of the univariate version
of this model, Norton [14] and Day et al. [33] used the
Gompertzian model of tumor growth in breast cancer and
derived fits to observed response duration curves using
simulation techniques [14], and numerical integration [33].
The Gompertzian model provided the background for the
dose-dense chemotherapy schedules [9, 10] which have
since been tested in clinical trials [11, 12] and implemented
in clinical practice. As with all pre-clinical hypotheses in
cancer, not all of these insights have been confirmed in
prospective clinical studies, but the mathematical model
described herein is a continuation of these lines of thought,
designed to quantify and add scientific rigor to these con-
cepts by analytically fitting such a model. This brings with
it related statistical techniques such as significance testing
and confidence intervals, as well as enabling a multivariate
form to become a practical tool for trial data interpretation.
This approach may be especially relevant in the era of
rationally designed targeted therapies, defining subgroups
where therapeutic interactions occur. The application of the
model warrants confirmation in future prospectively
designed clinical trials.
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